Condition
Pathological Processes
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 4 (2)
Trial Status
Terminated1
Unknown1
Completed1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04073290Phase 4Recruiting
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
NCT01092754Phase 4CompletedPrimary
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
NCT02681913Phase 2UnknownPrimary
Adenosine as an Adjunct to Blood Cardioplegia
NCT00527670TerminatedPrimary
Pilot Study to Identify the Influence of Genetic Profile Aberrations on Patients With Recurrent Hernias
Showing all 4 trials